Newron Pharmaceuticals SpA 2024 AR2
The report highlights Newron Pharmaceuticals' clinical and financial achievements in 2024, notably the exceptional data from its evenamide development program for schizophrenia. The company secured a major licensing agreement with EA Pharma for evenamide in Japan and other Asian territories, generating significant upfront and milestone payments. Financially, Newron recorded its first net profit since inception, amounting to EUR 15.8 million. On the ESG front, the company introduced a new anti-corruption policy, launched a whistleblowing service, and achieved its target of 33% female representation on the Board of Directors.
Company: Newron Pharmaceuticals SpA
Sector: Health Care
Country: Italy
Year: 2024
Type: AR2
Pages: 104
Newron Pharmaceuticals SpA
Annual Report
The report highlights Newron Pharmaceuticals' clinical and financial achievements in 2024, notably the exceptional data from its evenamide development program for schizophrenia. The company secured a major licensing agreement with EA Pharma for evenamide in Japan and other Asian territories, generating significant upfront and milestone payments. Financially, Newron recorded its first net profit since inception, amounting to EUR 15.8 million. On the ESG front, the company introduced a new anti-corruption policy, launched a whistleblowing service, and achieved its target of 33% female representation on the Board of Directors.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees